Conaway MR - Search Results

1

Imaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancer.

Scalici JM, Thomas S, Harrer C, Raines TA, Curran J, Atkins KA, Conaway MR, Duska L, Kelly KA, Slack-Davis JK. Scalici JM, et al. Among authors: conaway mr. J Nucl Med. 2013 Nov;54(11):1883-9. doi: 10.2967/jnumed.112.117796. Epub 2013 Sep 12. J Nucl Med. 2013. PMID: 24029657 Free PMC article.

2

Profiling the evolution of human metastatic bladder cancer.

Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D. Nicholson BE, et al. Among authors: conaway mr. Cancer Res. 2004 Nov 1;64(21):7813-21. doi: 10.1158/0008-5472.CAN-04-0826. Cancer Res. 2004. PMID: 15520187

3

Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis.

Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M. Slack-Davis JK, et al. Cancer Res. 2009 Feb 15;69(4):1469-76. doi: 10.1158/0008-5472.CAN-08-2678. Epub 2009 Feb 10. Cancer Res. 2009. PMID: 19208843

4

CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated.

Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, Smith SC, Frierson HF, Conaway M, Theodorescu D. Overdevest JB, et al. Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3588-96. doi: 10.1073/pnas.1113960109. Epub 2012 Sep 25. Proc Natl Acad Sci U S A. 2012. PMID: 23012401 Free PMC article.

5

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.

Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, Dutta A. Jazaeri AA, et al. Among authors: conaway mr. Mol Cancer Ther. 2013 Oct;12(10):1958-67. doi: 10.1158/1535-7163.MCT-12-1028. Epub 2013 Aug 12. Mol Cancer Ther. 2013. PMID: 23939375 Free PMC article.

6

Interobserver variability in the application of a proposed histologic subclassification of endocervical adenocarcinoma.

Paquette C, Jeffus SK, Quick CM, Conaway MR, Stoler MH, Atkins KA. Paquette C, et al. Among authors: conaway mr. Am J Surg Pathol. 2015 Jan;39(1):93-100. doi: 10.1097/PAS.0000000000000316. Am J Surg Pathol. 2015. PMID: 25188867

7

Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.

Curley J, Conaway MR, Chinn Z, Duska L, Stoler M, Mills AM. Curley J, et al. Among authors: conaway mr. Mod Pathol. 2020 Jun;33(6):1182-1192. doi: 10.1038/s41379-019-0433-3. Epub 2020 Mar 6. Mod Pathol. 2020. PMID: 32139873 Free article.

8

Breast Cancer Antiestrogen Resistance 3 (BCAR3) promotes tumor growth and progression in triple-negative breast cancer.

Arras J, Thomas KS, Myers PJ, Cross AM, Osei AD, Vazquez GE, Atkins KA, Conaway MR, Jones MK, Lazzara MJ, Bouton AH. Arras J, et al. Among authors: conaway mr. Am J Cancer Res. 2021 Oct 15;11(10):4768-4787. eCollection 2021. Am J Cancer Res. 2021. PMID: 34765292 Free PMC article.

9

RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.

Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D. Gildea JJ, et al. Among authors: conaway mr. Cancer Res. 2002 Nov 15;62(22):6418-23. Cancer Res. 2002. PMID: 12438227

10

Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.

Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr. Theodorescu D, et al. Among authors: conaway mr. Clin Cancer Res. 2004 Jun 1;10(11):3800-6. doi: 10.1158/1078-0432.CCR-03-0653. Clin Cancer Res. 2004. PMID: 15173088

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

267 results

Search Page